Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >API >Antineoplastic agents >Idiopathic pulmonary fibrosis(IPF) >Nintedanib

Nintedanib

Nintedanib Structure
CAS No.
656247-17-5
Chemical Name:
Nintedanib
Synonyms
Intedanib;Nintedanib (BIBF 1120);INTEDANIB BASE;methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene;(3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate;methyl (3Z)-2-hydroxy-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-3H-indole-6-carboxylate;100837;Nidanib;NTEDANIB;Vargatef
CBNumber:
CB72510401
Molecular Formula:
C31H33N5O4
Molecular Weight:
539.64
MOL File:
656247-17-5.mol
Modify Date:
2024/4/18 12:02:32
Request For Quotation

Nintedanib Properties

Melting point >237oC (dec.)
Boiling point 742.2±60.0 °C(Predicted)
Density 1.284±0.06 g/cm3(Predicted)
storage temp. Refrigerator
solubility DMSO (Slightly), Methanol (Slightly)
form Yellow solid.
pka 11.06±0.20(Predicted)
color Light Yellow to Light Green
InChIKey XZXHXSATPCNXJR-ZIADKAODSA-N
SMILES C(/C1C=CC=CC=1)(=C1\C(NC2=CC(C(=O)OC)=CC=C\12)=O)\NC1C=CC(N(C)C(=O)CN2CCN(C)CC2)=CC=1

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
NFPA 704
0
3 0

Nintedanib Chemical Properties,Uses,Production

Definition

ChEBI: A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.

Side effects

The most common side effects of Nintedanib in clinical studies were gastrointestinal-related side effects, including nausea (31%), vomiting (23%), diarrhoea (76%), abdominal pain (10%) and decreased appetite (10%). Other side effects were hepatic impairment commonly seen as elevated liver enzymes, weight loss (7 per cent), nasopharyngitis (7 per cent), cough (14 per cent), upper respiratory tract infections (14 per cent), headache (12 per cent), fatigue (14 per cent), skin ulcers (16 per cent) and urinary tract infections (12 per cent).
Reported post-marketing adverse events include gastrointestinal perforation, proteinuria and pancreatitis. In several clinical trials, nidanib has also been found to be associated with an increased risk of bleeding, possibly secondary to VEGFR inhibition. Although serious bleeding and arterial thromboembolic events (e.g., myocardial infarction (MI) and stroke) are rare, bleeding events with serious and fatal consequences have been reported in post-marketing surveillance. Therefore, the use of nidazanib has been associated with an increased risk of bleeding, possibly secondary to VEGFR inhibition. Therefore, patients treated with nidazanib and receiving full anticoagulation therapy need to be closely monitored for adverse bleeding events.

Nintedanib Preparation Products And Raw materials

Raw materials

N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide (E)-Methyl 1-acetyl-3-(Methoxy(phenyl)Methylene)-2-oxoindoline-6-carboxylate Nintedanib esylate 2,3-Dihydro-3-(MethoxyphenylMethylene)-2-oxo-1H-indole-6-carboxylic acid Methyl ester 1-Acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-2-oxo-1H-indole-6-carboxylic acid methyl ester
(3E)-2,3-Dihydro-3-(methoxyphenylmethylene)-2-oxo-1H-indole-6-carboxylic acid methyl ester Nintedanib Impurity 15
chevron_left

1of2

chevron_right

Preparation Products

Nintedanib Suppliers

Global( 380)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
HEMA PHARMACEUTICALS PVT LTD +91-9537936912 +91-9537936912 Gujarat, India 48 58 Inquiry
Metrochem API Private Limited +91-4069069999 +91-4069069999 Telangana, India 78 58 Inquiry
Glenmark Pharmaceuticals Limited +912240189999 Maharashtra, India 93 58 Inquiry
Apex Healthcare Limited +9199825711244 Gujarat, India 22 58 Inquiry
Sai Life Sciences Ltd +91-4066777555 +91-8008555365 Hyderabad, India 24 58 Inquiry
Shilpa Medicare Limited (SML) +91-8532238704 +91-9320649838 Karnataka, India 61 58 Inquiry
MSN LABORATORIES PRIVATE LTD +91 40 30438600 New Delhi, India 230 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
SynZeal Research Pvt Ltd +1 226-802-2078 Gujarat, India 6522 58 Inquiry
Supplier Advantage
HEMA PHARMACEUTICALS PVT LTD 58
Metrochem API Private Limited 58
Glenmark Pharmaceuticals Limited 58
Apex Healthcare Limited 58
Sai Life Sciences Ltd 58
Shilpa Medicare Limited (SML) 58
MSN LABORATORIES PRIVATE LTD 58
A.J Chemicals 58
CLEARSYNTH LABS LTD. 58
SynZeal Research Pvt Ltd 58

Related articles

Nintedanib Spectrum

Nintedanib(656247-17-5)MSNintedanib(656247-17-5)1HNMRNintedanib(656247-17-5)1HNMR

656247-17-5(Nintedanib)Related Search:

Infigratinib Trametinib Sunitinib Malate Ibrutinib Crizotinib
Neratinib LEE011 Alectinib Hydrochloride Nintedanib Ethanesulfonate Salt Olaparib
EAI-045 PLX-4720 Alectinib 1,3-DiMethyl 2-[4-(Methoxycarbonyl)-2-nitrophenyl]propanedioate 1-Chloro-4-(trimethoxymethyl)benzene
Nintedanib Impurity 76 ALPHA,ALPHA,2,4-TETRACHLOROTOLUENE 1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER
chevron_left

1of4

chevron_right
Nintedanib/Intedanib/Vargatef BIBF 1120; VARGATEF; INTEDANIB;INTEDANIB BASE Intedanib Vargatef Nintedanib, Free Base, >99% methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate NTEDANIB (3Z)-2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-Indole-6-carboxylic acid methyl ester methyl (Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate Methyl (Z)-3-[[[4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl]amino](phenyl)methylene]-2-oxoindoline-6-carboxylate BIBF-1120(Nintedanib,Vargatef) BIBF 1120; VARGATEF; INTEDANIB Vargatef Nintedanib whatsapp methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate Nintedanib (BIBF 1120) Vargatef (nintedanib) 3-[(4-{Methyl-[2-(4-methyl-piperazin-1-yl)-acetyl]-amino}-phenylamino)-phenyl-methylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Nintedanib-016 100837 Nintedanib (Intedanib) Vargatef (BIBF 1120, Intedanib) NINTEDANIB; BIBF1120; VARGATEF; BIBF-1120 Nidanib BIBF1120;VARGATEF;BIBF-1120 Intedanib (Nintedanib) 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- Nidanib ethane sulfonate Nintedanib USP/EP/BP Nintedanib (Vargatef High purity CAS 656247-17-5 Nintedanib in stock INTEDANIB BASE Nintedanib (BIBF 1120) methyl (3Z)-2-hydroxy-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-3H-indole-6-carboxylate Intedanib methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate FGFR,PDGFR,Nintedanib,Inhibitor,Platelet-derived growth factor receptor,Fibroblast growth factor receptor,Vascular endothelial growth factor receptor,VEGFR,BIBF1120,BIBF-1120,inhibit Methyl 2-hydroxy-3- N-[4-[methyl-[2-(4-methyIpiperazin- Methyl (Z)-3-[[[4-[N-Methyl-2-(4-methyl-1-piperazinyl)acetamido]phenyl]amino](phenyl)methylene]-2-oxoindoline-6-carboxylate Nidanib alkaloid 656247-17-5 C31H33O4N5 Heterocycles Intermediates & Fine Chemicals Pharmaceuticals Amines Nintedanib Inhibitors API API 656247-17-5